Unknown

Dataset Information

0

Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations.


ABSTRACT: Mycobacterium are among the oldest co-evolutionary partners of humans. The attenuated Mycobacterium bovis Bacillus Calmette Guérin (BCG) strain has been administered globally for 100 years as a vaccine against tuberculosis. BCG also shows promise as treatment for numerous inflammatory and autoimmune diseases. Here, we report on a randomized 8-year long prospective examination of type 1 diabetic subjects with long-term disease who received two doses of the BCG vaccine. After year 3, BCG lowered hemoglobin A1c to near normal levels for the next 5 years. The BCG impact on blood sugars appeared to be driven by a novel systemic and blood sugar lowering mechanism in diabetes. We observe a systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis, a state of high glucose utilization. Confirmation is gained by metabolomics, mRNAseq, and functional assays of cellular glucose uptake after BCG vaccinations. To prove BCG could induce a systemic change to promote accelerated glucose utilization and impact blood sugars, murine data demonstrated reduced blood sugars and aerobic induction in non-autoimmune mice made chemically diabetic. BCG via epigenetics also resets six central T-regulatory genes for genetic re-programming of tolerance. These findings set the stage for further testing of a known safe vaccine therapy for improved blood sugar control through changes in metabolism and durability with epigenetic changes even in advanced Type 1 diabetes.

SUBMITTER: Kuhtreiber WM 

PROVIDER: S-EPMC6013479 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations.

Kühtreiber Willem M WM   Tran Lisa L   Kim Taesoo T   Dybala Michael M   Nguyen Brian B   Plager Sara S   Huang Daniel D   Janes Sophie S   Defusco Audrey A   Baum Danielle D   Zheng Hui H   Faustman Denise L DL  

NPJ vaccines 20180621


<i>Mycobacterium</i> are among the oldest co-evolutionary partners of humans. The attenuated <i>Mycobacterium bovis</i> Bacillus Calmette Guérin (BCG) strain has been administered globally for 100 years as a vaccine against tuberculosis. BCG also shows promise as treatment for numerous inflammatory and autoimmune diseases. Here, we report on a randomized 8-year long prospective examination of type 1 diabetic subjects with long-term disease who received two doses of the BCG vaccine. After year 3,  ...[more]

Similar Datasets

| S-EPMC7205768 | biostudies-literature
| S-EPMC11315676 | biostudies-literature
| S-EPMC9668301 | biostudies-literature
| S-EPMC9376308 | biostudies-literature
| S-EPMC8906558 | biostudies-literature
| S-EPMC9287933 | biostudies-literature
| S-EPMC1185973 | biostudies-other
| S-EPMC9844159 | biostudies-literature
| S-EPMC4491996 | biostudies-literature
| S-EPMC2955101 | biostudies-literature